Irbesartan: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #134 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:Angiotensin receptor blockers]] | |||
[[Category:Antihypertensives]] | |||
Latest revision as of 10:43, 23 May 2026
Irbesartan
Avapro
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Hypertension0, Diabetic nephropathy (T2DM with proteinuria)0
Pharmacy
Starting dose
150 mg PO once daily; titrate to 300 mg if needed
Preparations
75, 150, 300 mg tablets
US FDA Max
300 mg/d
Pharmacology
Routes
Oral
Onset
BP effect within 1-2 weeks
Duration
24 hours
Half-life
11-15 hours[1]
Bioavailability
60-80% (oral; not significantly affected by food)[1]
Pregnancy
Contraindicated in pregnancy (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection[1]
Legal status
Rx-only in US
Purported mechanism
Irbesartan is a selective AT1 angiotensin-II receptor antagonist; blocking AT1 produces vasodilation, decreased aldosterone, and reduced sodium retention without the bradykinin accumulation that drives ACE-inhibitor cough.0 CYP2C9 substrate; no clinically active metabolites. The IDNT trial established renoprotection in diabetic nephropathy independent of BP lowering, contributing to the ARB class indication in T2DM with proteinuria[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Avapro (irbesartan), Sanofi-Aventis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020757s075lbl.pdf